Fueling metabolic disruption via FMD to boost chemotherapy in TNBC

IF 27.7 1区生物学 Q1 CELL BIOLOGY

Cell metabolism Pub Date : 2025-02-04 DOI:10.1016/j.cmet.2024.12.015

Marcus D. Goncalves, Neil M. Iyengar

引用次数: 0

Abstract

Triple-negative breast cancer (TNBC) is highly glycolytic and lacks effective biomarkers for therapy response. The BREAKFAST trial showed that a fasting-mimicking diet (FMD) improved pathological complete response (pCR) rates to 56.6% compared to historical chemotherapy averages (30%–40%), with minimal severe adverse events. FMD’s metabolic and immune-modulating effects warrant further study with immunotherapy.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell metabolism 生物-内分泌学与代谢

CiteScore

48.60

自引率

1.40%

发文量

173

审稿时长

2.5 months

期刊介绍： Cell Metabolism is a top research journal established in 2005 that focuses on publishing original and impactful papers in the field of metabolic research.It covers a wide range of topics including diabetes, obesity, cardiovascular biology, aging and stress responses, circadian biology, and many others. Cell Metabolism aims to contribute to the advancement of metabolic research by providing a platform for the publication and dissemination of high-quality research and thought-provoking articles.